185 related articles for article (PubMed ID: 37910098)
1. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP; Maqsood MH; Gelfand JM; Weber BN; Bangalore S; Lo Sicco KI; Garshick MS
JAMA Dermatol; 2024 Jan; 160(1):28-36. PubMed ID: 37910098
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.
Ireland PA; Jansson N; Spencer SKR; Braden J; Sebaratnam D
JAMA Dermatol; 2024 Mar; 160(3):281-289. PubMed ID: 38294793
[TBL] [Abstract][Full Text] [Related]
3. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.
Maqsood MH; Weber BN; Haberman RH; Lo Sicco KI; Bangalore S; Garshick MS
ACR Open Rheumatol; 2022 Oct; 4(10):912-922. PubMed ID: 35903881
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC; Bieber T; Alten R; Witte T; Galloway J; Deberdt W; Issa M; Haladyj E; De La Torre I; Grond S; Wollenberg A
Adv Ther; 2023 Apr; 40(4):1867-1883. PubMed ID: 36802049
[TBL] [Abstract][Full Text] [Related]
9. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
10. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185
[TBL] [Abstract][Full Text] [Related]
11. Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
Partalidou S; Patoulias D; Deuteraiou K; Avgerou P; Kitas G; Tzitiridou-Chatzopoulou M; Dimitroulas T
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):10-19. PubMed ID: 38756933
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.
Wei Q; Wang H; Zhao J; Luo Z; Wang C; Zhu C; Su N; Zhang S
Front Pharmacol; 2023; 14():1237234. PubMed ID: 37614310
[No Abstract] [Full Text] [Related]
14. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis.
Ertus C; Scailteux LM; Lescoat A; Berthe P; Auffret V; Dupuy A; Oger E; Droitcourt C
Br J Dermatol; 2023 Sep; 189(4):368-380. PubMed ID: 37410552
[TBL] [Abstract][Full Text] [Related]
15. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety.
Elmariah SB; Smith JS; Merola JF
Am J Clin Dermatol; 2022 Jul; 23(4):427-431. PubMed ID: 35679017
[TBL] [Abstract][Full Text] [Related]
16. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
17. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
18. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
20. Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses.
Alves C; Penedones A; Mendes D; Batel-Marques F
BMJ Open; 2020 Dec; 10(12):e041420. PubMed ID: 33384392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
